Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.34%61.300.0%$921.30m
NVAXNovavax, Inc. -2.58%101.87102.0%$804.56m
AMGNAmgen, Inc. -0.43%252.061.3%$730.38m
REGNRegeneron Pharmaceuticals, Inc. 0.46%643.832.5%$690.96m
GILDGilead Sciences, Inc. 0.01%76.431.0%$676.65m
BIIBBiogen, Inc. 4.78%281.171.6%$601.25m
VRTXVertex Pharmaceuticals, Inc. -0.61%297.231.9%$519.77m
ILMNIllumina, Inc. -0.30%371.013.5%$296.37m
ALXNAlexion Pharmaceuticals, Inc. -1.53%110.742.0%$226.69m
BMRNBioMarin Pharmaceutical, Inc. 0.12%128.134.3%$212.90m
SGENSeattle Genetics, Inc. -0.46%175.336.1%$206.84m
SRNESorrento Therapeutics, Inc. -2.03%7.231.8%$191.20m
IMMUImmunomedics, Inc. -0.10%41.1211.0%$177.92m
SRPTSarepta Therapeutics, Inc. 3.00%168.8113.9%$172.25m
INCYIncyte Corp. 0.41%109.102.5%$166.70m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.